Fervenza, Fernando C <br/><br/>
A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).  [electronic resource] 

 -  Nephron  2015 
 - 159-68 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2235-3186 
<br/><br/><label>Standard No.: </label>10.1159/000430849  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Angiotensin II Type 1 Receptor Blockers--therapeutic use<br/>B-Lymphocytes--drug effects<br/>Blood Pressure--drug effects<br/>Cyclosporine--adverse effects<br/>Endpoint Determination<br/>Female<br/>Glomerulonephritis, Membranous--drug therapy<br/>Humans<br/>Immunosuppressive Agents--adverse effects<br/>Male<br/>Middle Aged<br/>Patient Safety<br/>Proteinuria--drug therapy<br/>Rituximab--adverse effects<br/>Treatment Outcome<br/>Young Adult